Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity

BACKGROUND: In vivo use of monoclonal antibodies has become routine clinical practice in the treatment of human cancer. CD38 is an attractive target, because it has double roles, as a receptor and an ectoenzyme. Daratumumab, an anti-CD38 antibody, is currently in the clinical trials for multiple mye...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Tao, Qiao, Chunxia, Lv, Ming, Tang, Luqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530185/
https://www.ncbi.nlm.nih.gov/pubmed/31118070
http://dx.doi.org/10.1186/s12896-019-0524-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530185/
https://www.ncbi.nlm.nih.gov/pubmed/31118070
http://dx.doi.org/10.1186/s12896-019-0524-8

Ejemplares similares